Momenta Pharmaceuticals (MNTA) 11.70 $MNTA
3 Blockbuster Drugs That May Be Obsolete in 5 Years
Motley Fool Staff - Motley Fool - Sat Feb 07, 12:28PM CST
Blockbuster status is the Holy Grail for drug developers, but patent expirations mean these billion-dollar drugs have a limited shelf life. These three drugs, for example, have been among the planet's best-sellers, but over the course of the next...
JNJ: 99.62 (+1.18), BIIB: 391.66 (-0.45), ESRX: 84.90 (+0.40), PTLA: 34.96 (+3.13), PFE: 34.64 (-0.23), AZN: 69.96 (+0.20), TEVA: 56.77 (-0.58), GSK: 47.94 (+1.99), BMY: 60.04 (+0.56), MNTA: 11.70 (-0.06), NVS: 102.20 (-0.17)
Momenta Pharmaceuticals Is A Low-Risk, High-Reward Long-Term Gamble
Clinically Sound Investor - at Seeking Alpha - Sat Feb 07, 6:25AM CST
MNTA: 11.70 (-0.06)
Momenta Pharma reports February 17
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 8:19AM CST
MNTA: 11.70 (-0.06)
Momenta Pharmaceuticals Announces Date of Fourth Quarter and Year End 2014 Financial Results Conference Call and Webcast
GlobeNewswire - Tue Feb 03, 7:00AM CST
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the fourth quarter and year ended December 31, 2014 before the U.S. financial markets open on Tuesday, February 17, 2015.
MNTA: 11.70 (-0.06)
Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences
GlobeNewswire - Thu Jan 29, 7:00AM CST
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will webcast its presentation at two upcoming investor conferences.
MNTA: 11.70 (-0.06)
Downgrade Alert for Momenta Pharmaceuticals (MNTA)
Comtex SmarTrend(R) - Fri Jan 23, 8:05AM CST
Momenta Pharmaceuticals (NASDAQ:MNTA) was downgraded from Buy to Sell at Maxim today. The stock closed yesterday at $11.19 on volume of 1.5 million shares, above average daily volume of 554,000. Potential upside of 34.8% exists for Momenta Pharmaceuticals, based on a current level of $11.19 and analysts' average consensus price target of $15.08. Momenta Pharmaceuticals shares should first meet resistance at the 200-day moving average (MA) of $11.60 and find additional resistance at the 50-day MA of $11.83.
MNTA: 11.70 (-0.06)
Teva Up on Positive Copaxone Supreme Court Ruling - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 21, 3:00PM CST
Teva (TEVA) received a favorable Supreme Court ruling in its patent infringement lawsuit for Copaxone 20 mg/ml.
IPXL: 39.51 (+0.69), TEVA: 56.77 (-0.58), MNTA: 11.70 (-0.06), NVS: 102.20 (-0.17)
Momenta Pharmaceuticals Announces Supreme Court Decision to Remand Generic Copaxone(R) Case Back to CAFC
GlobeNewswire - Wed Jan 21, 7:38AM CST
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today announced that the United States Supreme Court has vacated the 2013 decision of the Court of Appeals for the Federal Circuit ("CAFC"
which found several of the Copaxone (20 mg injection) patents, including the one patent expiring September 1, 2015, invalid for being indefinite. The Supreme Court has overturned the long standing practice whereby the CAFC reviewed a District Court's claim interpretation "de novo," without deference to the District Court's claim interpretation, and ruled that the CAFC must instead give deference to the district court's findings of fact on issues of claim interpretation. The Supreme Court did not rule on the validity or invalidity of the patents per se, but has sent the case back to the CAFC to be reheard under the new deference standard.
MNTA: 11.70 (-0.06)
Supreme Court sides with Teva in drug dispute
By SAM HANANEL - AP - Tue Jan 20, 10:11AM CST
WASHINGTON (AP) — The Supreme Court on Tuesday sided with Teva Pharmaceutical Industries Ltd. in the company's high-profile patent dispute with rival firms over the top-selling multiple sclerosis drug.
MYL: 55.85 (+1.34), TEVA: 56.77 (-0.58), MNTA: 11.70 (-0.06)
Hold On To Teva!
Investing Tricks - at Seeking Alpha - Mon Dec 22, 2:09PM CST
MYL: 55.85 (+1.34), TEVA: 56.77 (-0.58), MNTA: 11.70 (-0.06), NVS: 102.20 (-0.17)
Metastatic Melanoma - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/2pb9ww/metastatic) has announced the addition of the "Metastatic Melanoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Melanoma and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Melanoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Metastatic Melanoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Vical Incorporated - Amgen Inc. - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - Genentech, Inc. - MedImmune, LLC - Plexxikon Inc. - Delcath Systems, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Eisai Co., Ltd. - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Celgene Corporation - Bayer AG - Incyte Corporation - Luitpold Pharmaceuticals, Inc. - Merck KGaA - Celldex Therapeutics, Inc. - Momenta Pharmaceuticals, Inc. - AVAX Technologies, Inc. - Oncolytics Biotech Inc. - Antisoma plc - Progen Pharmaceuticals Limited - HanAll Biopharma Co., Ltd. - Provectus Biopharmaceuticals, Inc. - BioAlliance Pharma SA For more information visit http://www.researchandmarkets.com/research/2pb9ww/metastatic
ONCY: 0.51 (+0.02), PFE: 34.64 (-0.23), INCY: 75.94 (+0.28), CLDX: 20.97 (+0.53), AMGN: 153.48 (+0.30), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), MNTA: 11.70 (-0.06), PVCT: 0.79 (-0.02), VICL: 1.01 (-0.01), AZN: 69.96 (+0.20), DCTH: 1.14 (+0.04), NVS: 102.20 (-0.17), CELGZ: 3.17 (-0.04)
Insider Trading Alert - DIN, AER And MNTA Traded By Insiders
at The Street - Mon Dec 15, 9:10AM CST
Stocks with insider trader activity include DIN, AER and MNTA
AER: 43.02 (+0.59), MNTA: 11.70 (-0.06), DIN: 104.49 (-0.51)
Teva Upgraded On Strength Of Copaxone MS Drug
at Investor's Business Daily - Fri Dec 12, 9:38AM CST
Sterne Agee upgraded Israeli drug giant Teva Pharmaceutical Industries (TEVA) to buy from neutral Friday, saying the outlook for its multiple-sclerosis drug Copaxone is better than most investors think. Teva issued 2015 guidance on Thursday morning,...
MYL: 55.85 (+1.34), TEVA: 56.77 (-0.58), MNTA: 11.70 (-0.06), NVS: 102.20 (-0.17)
Arthritis - Pipeline Review, H2 2014
M2 - Mon Dec 08, 3:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/42nbjz/arthritis) has announced the addition of the "Arthritis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Arthritis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Arthritis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Arthritis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Eli Lilly and Company - GlaxoSmithKline - Nemucore Medical Innovations - Taisho Pharmaceutical - Sylentis - Astellas Pharma - Eisai - Bone Medical - Momenta Pharmaceuticals - Can-Fite BioPharma - Lexicon Pharmaceuticals - CSL Limited - WhanIn Pharmaceutical - Oscotec Inc. - Viron Therapeutics - PLx Pharma - Endocyte - Cardax Pharmaceuticals - Taiwan Liposome Company - NasVax - CalciMedica - Zyngenia - SelectX Pharmaceuticals - DoNatur - CellAct Pharma - Arcarios - Inbiopro Solutions - Sagene Pharmaceuticals - vida therapeutics - Dong-A Socio For more information visit http://www.researchandmarkets.com/research/42nbjz/arthritis
CANF: 3.85 (+0.05), LXRX: 0.89 (unch), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), MNTA: 11.70 (-0.06)
Insider Trading Alert - NUVA, MNTA And AKR Traded By Insiders
at The Street - Wed Dec 03, 9:15AM CST
Stocks with insider trader activity include NUVA, MNTA and AKR
AKR: 35.47 (-0.38), MNTA: 11.70 (-0.06), NUVA: 46.99 (+0.30)
Momenta's Necuparanib Gets Fast Track Status in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 02, 2:10PM CST
Momenta Pharmaceuticals, Inc.'s (MNTA) necuparanib (plus Abraxane and Gemzar) received fast track designation from the FDA for metastatic pancreatic cancer.
BIIB: 391.66 (-0.45), BAX: 70.39 (+0.31), ABBV: 58.05 (+1.00), MNTA: 11.70 (-0.06)
Insider Trading Alert - SUBK, PDCO And MNTA Traded By Insiders
at The Street - Tue Dec 02, 9:17AM CST
Stocks with insider trader activity include SUBK, PDCO and MNTA
PDCO: 50.65 (-0.16), SUBK: 23.06 (+0.44), MNTA: 11.70 (-0.06)
Momenta cancer drug candidate Fast Track'd
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 10:24AM CST
MNTA: 11.70 (-0.06)
Momenta Pharmaceuticals' Necuparanib Receives Fast Track Designation From the FDA for the Treatment of Patients With Metastatic Pancreatic Cancer
GlobeNewswire - Mon Dec 01, 7:15AM CST
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigation of necuparanib, the Company's novel oncology drug candidate, as a first-line treatment in combination with Abraxaneand gemcitabine in patients with metastatic pancreatic cancer. Momenta recently announced the successful completion of Part A of the Phase 1/2 study and has initiated the Part B (Phase 2 proof-of-concept) study.
MNTA: 11.70 (-0.06)
Momenta Pharmaceuticals Announces Acceptance of a Clinical Trial Application in Europe for M923, a Biosimilar Version of Humira(R)
GlobeNewswire - Mon Dec 01, 7:00AM CST
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the acceptance by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) of a Clinical Trial Application (CTA) to initiate a clinical trial for M923, a biosimilar version of Humira (adalimumab), in its collaboration with Baxter International's biopharmaceutical business. Acceptance of the CTA triggers two milestones under the Baxter collaboration with an aggregate payment of $12 million. Momenta expects to receive the payment in December 2014.
BAX: 70.39 (+0.31), MNTA: 11.70 (-0.06)
3 Blockbuster Drugs That May Be Obsolete in 5 Years
Motley Fool Staff - Motley Fool - Sat Feb 07, 12:28PM CST
Blockbuster status is the Holy Grail for drug developers, but patent expirations mean these billion-dollar drugs have a limited shelf life. These three drugs, for example, have been among the planet's best-sellers, but over the course of the next...
JNJ: 99.62 (+1.18), BIIB: 391.66 (-0.45), ESRX: 84.90 (+0.40), PTLA: 34.96 (+3.13), PFE: 34.64 (-0.23), AZN: 69.96 (+0.20), TEVA: 56.77 (-0.58), GSK: 47.94 (+1.99), BMY: 60.04 (+0.56), MNTA: 11.70 (-0.06), NVS: 102.20 (-0.17)
Momenta Pharmaceuticals Is A Low-Risk, High-Reward Long-Term Gamble
Clinically Sound Investor - at Seeking Alpha - Sat Feb 07, 6:25AM CST
MNTA: 11.70 (-0.06)
Momenta Pharma reports February 17
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 8:19AM CST
MNTA: 11.70 (-0.06)
Momenta Pharmaceuticals Announces Date of Fourth Quarter and Year End 2014 Financial Results Conference Call and Webcast
GlobeNewswire - Tue Feb 03, 7:00AM CST
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the fourth quarter and year ended December 31, 2014 before the U.S. financial markets open on Tuesday, February 17, 2015.
MNTA: 11.70 (-0.06)
Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences
GlobeNewswire - Thu Jan 29, 7:00AM CST
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will webcast its presentation at two upcoming investor conferences.
MNTA: 11.70 (-0.06)
Downgrade Alert for Momenta Pharmaceuticals (MNTA)
Comtex SmarTrend(R) - Fri Jan 23, 8:05AM CST
Momenta Pharmaceuticals (NASDAQ:MNTA) was downgraded from Buy to Sell at Maxim today. The stock closed yesterday at $11.19 on volume of 1.5 million shares, above average daily volume of 554,000. Potential upside of 34.8% exists for Momenta Pharmaceuticals, based on a current level of $11.19 and analysts' average consensus price target of $15.08. Momenta Pharmaceuticals shares should first meet resistance at the 200-day moving average (MA) of $11.60 and find additional resistance at the 50-day MA of $11.83.
MNTA: 11.70 (-0.06)
Teva Up on Positive Copaxone Supreme Court Ruling - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 21, 3:00PM CST
Teva (TEVA) received a favorable Supreme Court ruling in its patent infringement lawsuit for Copaxone 20 mg/ml.
IPXL: 39.51 (+0.69), TEVA: 56.77 (-0.58), MNTA: 11.70 (-0.06), NVS: 102.20 (-0.17)
Momenta Pharmaceuticals Announces Supreme Court Decision to Remand Generic Copaxone(R) Case Back to CAFC
GlobeNewswire - Wed Jan 21, 7:38AM CST
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today announced that the United States Supreme Court has vacated the 2013 decision of the Court of Appeals for the Federal Circuit ("CAFC"
which found several of the Copaxone (20 mg injection) patents, including the one patent expiring September 1, 2015, invalid for being indefinite. The Supreme Court has overturned the long standing practice whereby the CAFC reviewed a District Court's claim interpretation "de novo," without deference to the District Court's claim interpretation, and ruled that the CAFC must instead give deference to the district court's findings of fact on issues of claim interpretation. The Supreme Court did not rule on the validity or invalidity of the patents per se, but has sent the case back to the CAFC to be reheard under the new deference standard. MNTA: 11.70 (-0.06)
Supreme Court sides with Teva in drug dispute
By SAM HANANEL - AP - Tue Jan 20, 10:11AM CST
WASHINGTON (AP) — The Supreme Court on Tuesday sided with Teva Pharmaceutical Industries Ltd. in the company's high-profile patent dispute with rival firms over the top-selling multiple sclerosis drug.
MYL: 55.85 (+1.34), TEVA: 56.77 (-0.58), MNTA: 11.70 (-0.06)
Hold On To Teva!
Investing Tricks - at Seeking Alpha - Mon Dec 22, 2:09PM CST
MYL: 55.85 (+1.34), TEVA: 56.77 (-0.58), MNTA: 11.70 (-0.06), NVS: 102.20 (-0.17)
Metastatic Melanoma - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/2pb9ww/metastatic) has announced the addition of the "Metastatic Melanoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Melanoma and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Melanoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Metastatic Melanoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Vical Incorporated - Amgen Inc. - Sanofi - AstraZeneca PLC - GlaxoSmithKline plc - Genentech, Inc. - MedImmune, LLC - Plexxikon Inc. - Delcath Systems, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Eisai Co., Ltd. - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Celgene Corporation - Bayer AG - Incyte Corporation - Luitpold Pharmaceuticals, Inc. - Merck KGaA - Celldex Therapeutics, Inc. - Momenta Pharmaceuticals, Inc. - AVAX Technologies, Inc. - Oncolytics Biotech Inc. - Antisoma plc - Progen Pharmaceuticals Limited - HanAll Biopharma Co., Ltd. - Provectus Biopharmaceuticals, Inc. - BioAlliance Pharma SA For more information visit http://www.researchandmarkets.com/research/2pb9ww/metastatic
ONCY: 0.51 (+0.02), PFE: 34.64 (-0.23), INCY: 75.94 (+0.28), CLDX: 20.97 (+0.53), AMGN: 153.48 (+0.30), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), MNTA: 11.70 (-0.06), PVCT: 0.79 (-0.02), VICL: 1.01 (-0.01), AZN: 69.96 (+0.20), DCTH: 1.14 (+0.04), NVS: 102.20 (-0.17), CELGZ: 3.17 (-0.04)
Insider Trading Alert - DIN, AER And MNTA Traded By Insiders
at The Street - Mon Dec 15, 9:10AM CST
Stocks with insider trader activity include DIN, AER and MNTA
AER: 43.02 (+0.59), MNTA: 11.70 (-0.06), DIN: 104.49 (-0.51)
Teva Upgraded On Strength Of Copaxone MS Drug
at Investor's Business Daily - Fri Dec 12, 9:38AM CST
Sterne Agee upgraded Israeli drug giant Teva Pharmaceutical Industries (TEVA) to buy from neutral Friday, saying the outlook for its multiple-sclerosis drug Copaxone is better than most investors think. Teva issued 2015 guidance on Thursday morning,...
MYL: 55.85 (+1.34), TEVA: 56.77 (-0.58), MNTA: 11.70 (-0.06), NVS: 102.20 (-0.17)
Arthritis - Pipeline Review, H2 2014
M2 - Mon Dec 08, 3:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/42nbjz/arthritis) has announced the addition of the "Arthritis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Arthritis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Arthritis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Arthritis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Eli Lilly and Company - GlaxoSmithKline - Nemucore Medical Innovations - Taisho Pharmaceutical - Sylentis - Astellas Pharma - Eisai - Bone Medical - Momenta Pharmaceuticals - Can-Fite BioPharma - Lexicon Pharmaceuticals - CSL Limited - WhanIn Pharmaceutical - Oscotec Inc. - Viron Therapeutics - PLx Pharma - Endocyte - Cardax Pharmaceuticals - Taiwan Liposome Company - NasVax - CalciMedica - Zyngenia - SelectX Pharmaceuticals - DoNatur - CellAct Pharma - Arcarios - Inbiopro Solutions - Sagene Pharmaceuticals - vida therapeutics - Dong-A Socio For more information visit http://www.researchandmarkets.com/research/42nbjz/arthritis
CANF: 3.85 (+0.05), LXRX: 0.89 (unch), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), MNTA: 11.70 (-0.06)
Insider Trading Alert - NUVA, MNTA And AKR Traded By Insiders
at The Street - Wed Dec 03, 9:15AM CST
Stocks with insider trader activity include NUVA, MNTA and AKR
AKR: 35.47 (-0.38), MNTA: 11.70 (-0.06), NUVA: 46.99 (+0.30)
Momenta's Necuparanib Gets Fast Track Status in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 02, 2:10PM CST
Momenta Pharmaceuticals, Inc.'s (MNTA) necuparanib (plus Abraxane and Gemzar) received fast track designation from the FDA for metastatic pancreatic cancer.
BIIB: 391.66 (-0.45), BAX: 70.39 (+0.31), ABBV: 58.05 (+1.00), MNTA: 11.70 (-0.06)
Insider Trading Alert - SUBK, PDCO And MNTA Traded By Insiders
at The Street - Tue Dec 02, 9:17AM CST
Stocks with insider trader activity include SUBK, PDCO and MNTA
PDCO: 50.65 (-0.16), SUBK: 23.06 (+0.44), MNTA: 11.70 (-0.06)
Momenta cancer drug candidate Fast Track'd
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 10:24AM CST
MNTA: 11.70 (-0.06)
Momenta Pharmaceuticals' Necuparanib Receives Fast Track Designation From the FDA for the Treatment of Patients With Metastatic Pancreatic Cancer
GlobeNewswire - Mon Dec 01, 7:15AM CST
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigation of necuparanib, the Company's novel oncology drug candidate, as a first-line treatment in combination with Abraxaneand gemcitabine in patients with metastatic pancreatic cancer. Momenta recently announced the successful completion of Part A of the Phase 1/2 study and has initiated the Part B (Phase 2 proof-of-concept) study.
MNTA: 11.70 (-0.06)
Momenta Pharmaceuticals Announces Acceptance of a Clinical Trial Application in Europe for M923, a Biosimilar Version of Humira(R)
GlobeNewswire - Mon Dec 01, 7:00AM CST
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the acceptance by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) of a Clinical Trial Application (CTA) to initiate a clinical trial for M923, a biosimilar version of Humira (adalimumab), in its collaboration with Baxter International's biopharmaceutical business. Acceptance of the CTA triggers two milestones under the Baxter collaboration with an aggregate payment of $12 million. Momenta expects to receive the payment in December 2014.
BAX: 70.39 (+0.31), MNTA: 11.70 (-0.06)
